Karyopharm therapeutics inc. announces xpovio® (selinexor) clinical data to be presented at the american society of hematology 2019 annual meeting

Karyopharm therapeutics inc. announced that thirteen abstracts have been selected for presentation, including one oral presentation, at the upcoming american society of hematology (ash) 2019 annual meeting taking place december 7-10, 2019 in orlando. four key abstracts to be presented at the meeting will feature clinical data for xpovio® (selinexor), the company’s first in class, oral sine compound, including: updated data from the pomalyst® (pomalidomide) and kyprolis® (carfilzomib) arms of the phase 1b/2 stomp study evaluating selinexor in combination with backbone therapies in patients with relapsed or refractory multiple myeloma; new data from the revlimid® (lenalidomide) plus selinexor arm of the phase 1b/2 stomp study evaluating this combination in patients with newly diagnosed multiple myeloma; and new data reporting on the use of selinexor in multiple myeloma patients whose disease has progressed following chimeric antigen receptor t-cell (car-t) therapy. other abstracts at the meeting include: encore data highlighting the previously disclosed comparison of patients in the storm study to matched patients from the mammoth study; a post-hoc analysis from the phase 2b storm study evaluating the efficacy and safety of xpovio in patients with triple-class refractory multiple myeloma with high risk cytogenetics; an additional analysis from the storm study evaluating xpovio in patients with plasmacytomas; and a summary of new scientific research that identified a genetic model that predicts sensitivity to selinexor. in addition, phase 1/2 data evaluating eltanexor, karyopharm’s next generation sine compound, in patients with higher-risk myelodysplastic syndrome will be presented showing encouraging activity with tolerability. finally, data from four investigator-sponsored studies including selinexor plus ibrutinib will be featured further showing the potential for sine technology.
KPTI Ratings Summary
KPTI Quant Ranking